Influence of type of starch and feeding management

Affect of kind of starch and feeding administration on glycaemic management in diabetic canine

  • The current research evaluated the consequences of two diets with completely different starch sources and two feeding strategies on the glycaemic management in canine with diabetes mellitus. The diets had related nutrient contents (40% starch and 16% dietary fibre), one formulated with 46% of damaged rice and the opposite with 42% sorghum and 10% lentils (as-fed).
  • Ten client-owned diabetic canine had been fed with every weight loss plan for two months, in a crossover design. 5 canine obtained NPH human insulin and meals each 12 h (feeding technique 1), and the opposite 5 obtained insulin each 12 h however had been fed 3 times a day (feeding technique 2). In feeding technique 2, morning insulin was larger than the night dose and canine obtained the second meal after Four to five h of the morning insulin and meal.
  • Parameters evaluated included insulin dosage, 12- and 8-h glycaemic curves, full blood rely, biochemical profile and urinalysis. Glycaemic curves had been analysed by ANOVA with repeated measures. Glycaemic management parameters (fasting, imply, minimal and most glycaemia and serum fructosamine) and glucose space underneath the curve (AUC) had been calculated and analysed by paired t check (p < 0.05). In feeding technique 1, canine fed the sorghum-based weight loss plan offered decrease imply (p = 0.04) and minimal blood glucose concentrations (p = 0.03), and an inclination to decrease most blood glucose (p = 0.06) and glucose AUC (p = 0.08) than when fed the rice-based weight loss plan.
  • When meals was offered twice a day, the ingestion of the rice-based weight loss plan resulted in larger post-prandial glucose response than the weight loss plan with sorghum and lentil. In feeding technique 2, there was no impact of weight loss plan on the assessed parameters (p > 0.05).
  • No variations in insulin dosage had been noticed between teams or feeding strategies (p > 0.05). Offering two meals a day adopted by insulin administration related to the sorghum- and lentil-based weight loss plan improved glycaemic management in diabetic canine.
insuline-medical
insuline-medical

RRAD Antibody

CSB-PA233809-100ul 100ul
EUR 379.2
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

RRAD Antibody

1-CSB-PA248209
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100

RRAD Antibody

GWB-MU399C 50ug Ask for price

RRAD Antibody

GWB-MU400D 50ug Ask for price

RRAD Antibody

R34275-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Ras-related associated with diabetes

RRAD Antibody

MBS7132819-01mL 0.1mL
EUR 270

RRAD Antibody

MBS7132819-5x01mL 5x0.1mL
EUR 1200

RRAD Antibody

MBS7128139-005mL 0.05mL
EUR 190

RRAD Antibody

MBS7128139-01mL 0.1mL
EUR 270

RRAD Antibody

MBS7128139-5x01mL 5x0.1mL
EUR 1205

RRAD Antibody

MBS7128140-005mL 0.05mL
EUR 190

RRAD Antibody

MBS7128140-01mL 0.1mL
EUR 270

RRAD Antibody

MBS7128140-5x01mL 5x0.1mL
EUR 1205

RRAD Antibody

MBS7116925-005mg 0.05mg
EUR 150

RRAD Antibody

MBS7116925-01mg 0.1mg
EUR 190

RRAD Antibody

MBS7116925-5x01mg 5x0.1mg
EUR 845

RRAD Antibody

MBS9412639-01mL 0.1mL
EUR 305

RRAD Antibody

MBS9412639-5x01mL 5x0.1mL
EUR 1230

RRAD Antibody

MBS9202899-01mL 0.1mL
EUR 415

RRAD Antibody

MBS9202899-5x01mL 5x0.1mL
EUR 1841

RRAD Antibody

MBS8581027-01mL 0.1mL
EUR 305

RRAD Antibody

MBS8581027-01mLAF405L 0.1mL(AF405L)
EUR 465

RRAD Antibody

MBS8581027-01mLAF405S 0.1mL(AF405S)
EUR 465

RRAD Antibody

MBS8581027-01mLAF610 0.1mL(AF610)
EUR 465

RRAD Antibody

MBS8581027-01mLAF635 0.1mL(AF635)
EUR 465

RRAD Antibody

MBS5314978-01mL 0.1mL
EUR 470

RRAD Antibody

MBS5314978-5x01mL 5x0.1mL
EUR 1955

Polyclonal RRAD Antibody

APR05556G 0.1ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications:

RRAD antibody - middle region

MBS3212856-01mL 0.1mL
EUR 455

RRAD antibody - middle region

MBS3212856-5x01mL 5x0.1mL
EUR 1995

RRAD antibody - middle region

MBS3212857-01mL 0.1mL
EUR 455

RRAD antibody - middle region

MBS3212857-5x01mL 5x0.1mL
EUR 1995

OAAF03734-100UG - RRAD Antibody

OAAF03734-100UG 100ug
EUR 329

RRAD Conjugated Antibody

C37229 100ul
EUR 476.4

RRAD Polyclonal Antibody

E-AB-16047-120uL 120uL
EUR 240
Description: Unconjugated

RRAD Polyclonal Antibody

E-AB-16047-200uL 200uL
EUR 399
Description: Unconjugated

RRAD Polyclonal Antibody

E-AB-16047-20uL 20uL
EUR 73
Description: Unconjugated

RRAD Polyclonal Antibody

E-AB-16047-60uL 60uL
EUR 143
Description: Unconjugated

RRAD Polyclonal Antibody

MBS2528424-002mL 0.02mL
EUR 140

RRAD Polyclonal Antibody

MBS2528424-006mL 0.06mL
EUR 180

RRAD Polyclonal Antibody

MBS2528424-012mL 0.12mL
EUR 260

RRAD Polyclonal Antibody

MBS2528424-02mL 0.2mL
EUR 405

RRAD Polyclonal Antibody

MBS2528424-5x02mL 5x0.2mL
EUR 1725

RRAD Polyclonal Antibody

MBS2528620-002mL 0.02mL
EUR 135

RRAD Polyclonal Antibody

MBS2528620-006mL 0.06mL
EUR 190

RRAD Polyclonal Antibody

MBS2528620-012mL 0.12mL
EUR 265

RRAD Polyclonal Antibody

MBS2528620-02mL 0.2mL
EUR 415

RRAD Polyclonal Antibody

MBS2528620-5x02mL 5x0.2mL
EUR 1835

RRAD Conjugated Antibody

MBS9447672-01mLAF350 0.1mL(AF350)
EUR 480

RRAD Conjugated Antibody

MBS9447672-01mLAF405 0.1mL(AF405)
EUR 480

RRAD Conjugated Antibody

MBS9447672-01mLAF488 0.1mL(AF488)
EUR 480

RRAD Conjugated Antibody

MBS9447672-01mLAF555 0.1mL(AF555)
EUR 480

RRAD Conjugated Antibody

MBS9447672-01mLBiotin 0.1mL(Biotin)
EUR 480

RRAD Polyclonal Antibody

RD78747A-120uL 120μL
EUR 360
Description: The protein may be important in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca2+ currents. As regulator of voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane. Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway and phosphorylation and activation of CAMK2D. Mostly expressed in the heart and muscle of type II diabetic humans. Also found in the skeletal muscle, lung and adipose tissue. Lesser amounts in placenta and kidney.

RRAD Polyclonal Antibody

RD78747A-200uL 200μL
EUR 630
Description: The protein may be important in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca2+ currents. As regulator of voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane. Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway and phosphorylation and activation of CAMK2D. Mostly expressed in the heart and muscle of type II diabetic humans. Also found in the skeletal muscle, lung and adipose tissue. Lesser amounts in placenta and kidney.

RRAD Polyclonal Antibody

RD78747A-20uL 20μL
EUR 109.5
Description: The protein may be important in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca2+ currents. As regulator of voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane. Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway and phosphorylation and activation of CAMK2D. Mostly expressed in the heart and muscle of type II diabetic humans. Also found in the skeletal muscle, lung and adipose tissue. Lesser amounts in placenta and kidney.

RRAD Polyclonal Antibody

RD78747A-60uL 60μL
EUR 214.5
Description: The protein may be important in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca2+ currents. As regulator of voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane. Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway and phosphorylation and activation of CAMK2D. Mostly expressed in the heart and muscle of type II diabetic humans. Also found in the skeletal muscle, lung and adipose tissue. Lesser amounts in placenta and kidney.

RRAD Rabbit Polyclonal Antibody

E10G04435 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

RRAD Rabbit Polyclonal Antibody

E10G11330 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

GTP-Binding Protein RAD (RRAD) Antibody

20-abx008742
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

GTP-binding protein RAD (RRAD) Antibody

20-abx214509
  • Ask for price
  • Ask for price
  • 100 ul
  • 50 ul

GTP-binding protein RAD (RRAD) Antibody

abx332370-100ul 100 ul
EUR 510

GTP-binding protein RAD (RRAD) Antibody

20-abx324872
  • Ask for price
  • Ask for price
  • 100 ug
  • 50 ug

GTP-Binding Protein RAD (RRAD) Antibody

abx432011-200ul 200 ul
EUR 460.8

GTP-binding protein RAD (RRAD) Antibody

20-abx241706
  • Ask for price
  • Ask for price
  • 100 ul
  • 50 ul

GTP-binding protein RAD (RRAD) Antibody

abx241706-96tests 96 tests
EUR 250

GTP-binding protein RAD (RRAD) Antibody

abx214509-100tests 100 tests
EUR 350

GTP-binding protein RAD (RRAD) Antibody

abx214509-200tests 200 tests Ask for price

GTP-binding protein RAD (RRAD) Antibody

abx214509-20tests 20 tests
EUR 250

GTP-binding protein RAD (RRAD) Antibody

abx324872-100g 100 µg
EUR 250

GTP-binding protein RAD (RRAD) Antibody

abx324872-50g 50 µg
EUR 187.5

GTP-Binding Protein RAD (RRAD) Antibody

abx432011-100g 100 µg
EUR 387.5

ARP56566_P050-25UL - RRAD Antibody - middle region

ARP56566_P050-25UL 25ul
EUR 99

ARP56567_P050-25UL - RRAD Antibody - middle region

ARP56567_P050-25UL 25ul
EUR 99

OASG06195-100UL - RRAD Antibody - middle region

OASG06195-100UL 100ul
EUR 239

OAEB02919-100UG - RRAD Antibody - middle region

OAEB02919-100UG 100ug
EUR 349

ARP56566_P050 - RRAD antibody - middle region (ARP56566_P050)

ARP56566_P050 100ul
EUR 389

ARP56567_P050 - RRAD antibody - middle region (ARP56567_P050)

ARP56567_P050 100ul
EUR 389

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx122938-100ug 100 ug
EUR 469.2

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx237237-100ug 100 ug
EUR 661.2

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx122938-100l 100 µl Ask for price

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx122938-20l 20 µl
EUR 337.5

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx122938-50l 50 µl Ask for price

RRAD And GEM Like GTPase 2 (REM2) Antibody

abx237237-100g 100 µg
EUR 350

Polyclonal RRAD (aa36-48) Antibody (internal region)

APG00807G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications:

RRAD siRNA

20-abx932133
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

RRAD Peptide

43-008P 0.1 mg
EUR 405.6
Description: RRAD Peptide

RRAD Rabbit anti-Human Polyclonal (aa107-156) Antibody

MBS2402152-005mL 0.05mL
EUR 615

RRAD Rabbit anti-Human Polyclonal (aa107-156) Antibody

MBS2402152-5x005mL 5x0.05mL
EUR 2605

RRAD siRNA (Human)

MBS8215484-15nmol 15nmol
EUR 405

RRAD siRNA (Human)

MBS8215484-30nmol 30nmol
EUR 565

RRAD siRNA (Human)

MBS8215484-5x30nmol 5x30nmol
EUR 2450

RRAD Blocking Peptide

20-abx063234
  • Ask for price
  • Ask for price
  • 1 mg
  • 5 mg

RRAD Blocking Peptide

33R-10070 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798

RRAD Blocking Peptide

33R-4793 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797

RRAD Blocking Peptide

MBS823418-1mg 1mg
EUR 190

RRAD Blocking Peptide

MBS823418-5mg 5mg
EUR 345

RRAD Blocking Peptide

MBS823418-5x5mg 5x5mg
EUR 1465

RRAD Immunizing Peptide

MBS427795-01mg 0.1mg
EUR 225

Rrad (GFP-tagged) - Mouse Ras-related associated with diabetes (Rrad)

MG204351 10 µg Ask for price

Rrad (untagged) - Mouse Ras-related associated with diabetes (Rrad), (10ug)

MC203288 10 µg Ask for price

RRAD (NM_001128850) Human Recombinant Protein

PROTP55042 20ug
EUR 1249
Description: Recombinant protein of human Ras-related associated with diabetes (RRAD), transcript variant 1

Rat Rrad ELISA Kit

ELI-14921r 96tests
EUR 756

Rat Rrad ELISA Kit

EF019253 96tests
EUR 566

Rrad (Myc-DDK-tagged) - Mouse Ras-related associated with diabetes (Rrad)

MR204351 10 µg Ask for price

Mouse Rrad ELISA Kit

EF016057 96tests
EUR 566

Human RRAD ELISA KIT

EF005507 96tests
EUR 566

Human RRAD shRNA Plasmid

20-abx954199
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Rrad (untagged ORF) - Rat Ras-related associated with diabetes (Rrad), (10 ug)

RN208148 10 µg Ask for price

Human RRAD Protein Lysate

MBS8418875-002mg 0.02mg
EUR 365

Associations between attainment of incentivized main care indicators and incident decrease limb amputation amongst these with kind 2 diabetes: a population-based historic cohort research

Introduction: England has invested significantly in diabetes care by way of such packages because the High quality and Outcomes Framework (QOF) and Nationwide Diabetes Audit (NDA). Associations between program indicators and scientific endpoints, similar to amputation, stay unclear. We examined associations between main care indicators and incident decrease limb amputation.

Analysis design and strategies: This population-based retrospective cohort research, spanning 2010-2017, was comprised of adults in England with kind 2 diabetes and no historical past of decrease limb amputation. Exposures at baseline (2010-2011) had been attainment of QOF glycated hemoglobin (HbA1c), blood stress and whole ldl cholesterol indicators, and variety of NDA processes accomplished.

Propensity rating matching was carried out and multivariable Cox proportional hazards fashions, adjusting for disease-related, comorbidity, way of life, and sociodemographic elements, had been fitted utilizing matched samples for every publicity.

Outcomes: 83 688 people from 330 English main care practices had been included. Imply follow-up was 3.9 (SD 2.0) years, and 521 (0.6%) minor or main amputations had been noticed (1.62 per 1000 person-years). HbA1c and ldl cholesterol indicator attainment had been related to significantly decrease dangers of minor or main amputation (adjusted HRs; 95% CIs) 0.61 (0.49 to 0.74; p<0.0001) and 0.67 (0.53 to 0.86; p=0.0017), respectively). No proof of affiliation between blood stress indicator attainment and amputation was noticed (adjusted HR 0.88 (0.73 to 1.06; p=0.1891)).

Considerably decrease amputation charges had been noticed amongst these finishing a larger variety of NDA care processes (adjusted HRs 0.45 (0.24 to 0.83; p=0.0106), 0.67 (0.47 to 0.97; p=0.0319), and 0.38 (0.20 to 0.70; p=0.0022) for comparisons of 4-6 vs 0-3, 7-9 vs 0-3, and 7-9 vs 4-6 processes, respectively). Outcomes for major-only amputations had been related for HbA1c and blood stress, although ldl cholesterol indicator attainment was non-significant.

Conclusions: Complete main care-based secondary prevention might supply appreciable safety in opposition to diabetes-related amputation. This has necessary implications for diabetes administration and medical decision-making for sufferers, in addition to kind 2 diabetes high quality enchancment packages.

 

The pattern-recognition molecule H-ficolin in relation to diabetic kidney illness, mortality, and cardiovascular occasions in kind 1 diabetes

H-ficolin acknowledges patterns on microorganisms and burdened cells and may activate the lectin pathway of the complement system. We aimed to evaluate H-ficolin in relation to the development of diabetic kidney illness (DKD), all-cause mortality, diabetes-related mortality, and cardiovascular occasions.

Occasion charges per 10-unit H-ficolin-increase had been in contrast in an observational follow-up of two,410 people with kind 1 diabetes from the FinnDiane Research. DKD development occurred in 400 people. The unadjusted hazard ratio (HR) for development was 1.29 (1.18-1.40) and 1.16 (1.05-1.29) after adjustment for diabetes length, intercourse, HbA1c, systolic blood stress, and smoking standing.

After including triglycerides to the mannequin, the HR decreased to 1.07 (0.97-1.18). In all, 486 people died, together with 268 deaths of cardiovascular causes and 192 deaths of problems to diabetes. HRs for all-cause mortality and cardiovascular mortality had been 1.13 (1.04-1.22) and 1.05 (0.93-1.17), respectively, in unadjusted analyses. These estimates misplaced statistical significance in adjusted fashions.

Nevertheless, the unadjusted HR for diabetes-related mortality was 1.19 (1.05-1.35) and 1.18 (1.02-1.37) with probably the most stringent adjustment stage. Our outcomes, due to this fact, point out that H-ficolin predicts diabetes-related mortality, however neither all-cause mortality nor deadly/non-fatal cardiovascular occasions. Moreover, H-ficolin is related to DKD development, nevertheless, not independently of the totally adjusted mannequin.

The worth of glycosylated hemoglobin within the prognosis of diabetic retinopathy: a scientific evaluate and Meta-analysis

 Goal: Glycosylated hemoglobin (HbA1c) has apparent scientific worth within the prognosis of diabetes, however the conclusions on the diagnostic worth of diabetic retinopathy (DR) should not constant. This research goals to comprehensively consider the accuracy of glycosylated hemoglobin within the prognosis of diabetic retinopathy by way of the meta-analysis of diagnostic checks.

Strategies: Cochrane Library, Embase, PubMed, Net of Science, China Nationwide Information Infrastructure (CNKI), China Wanfang Database, Chinese language Biomedical Literature Database (CBM) had been searched till November, 2020. The High quality Evaluation of Diagnostic Accuracy Research-2 (QUADAS-2) software was used to evaluate the standard of the included research. The pooled sensitivity, specificity, optimistic probability ratio (+LR), unfavourable probability ratio (-LR), diagnostic odds ratio (DOR) and areas underneath the receiver working attribute (ROC) curve had been calculated by Stata 15.Zero software program.

Outcomes: After screening, 18 high-quality papers had been included. The outcomes of meta-analysis confirmed that the mixed DOR = 18.19 (95% CI: 10.99-30.11), the sensitivity= 0.81 (95% CI): 0.75 ~ 0.87), specificity = 0.81 (95%CI: 0.72 ~ 0.87), +LR = 4.2 (95%CI: 2.95 ~ 6.00), -LR = 0.23 (95%CI: 0.17 ~ 0.31), and the world underneath the Abstract ROC curve was 0.88 (95%CI: 0.85 ~ 0.90).

Conclusion: The general accuracy of HbA1cC forin diagnosing diabetic retinopathy is sweet. As it’s extra secure than blood sugar and isn’t affected by meals, it might be an acceptable indicator for diabetic retinopathy.

Human Muscle Myoblasts, Diabetes Type II

ABC-TC3957 1 vial Ask for price
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support.

Human Type 1 Diabetes Leukopak

ABC-TC4310 1 pack Ask for price
Description: RI dependent diabetes, or Type 1 Diabetes is caused by the pancreas producing little to no RI.

HighQC™ Human IPS Cell (Type 2 Diabetes)

ABC-SC0005T 1 vial Ask for price
Description: Induced Pluriopotent Stem Cells (iPSCs) are a type of pluripotent stem cells that can be derived directly from adult somatic cells . The derived iPSCs can propagate indefinitely, as well as give rise to other cell types in the body. iPS cells, thus, hold great promise in the field of regenerative medicine by representing a single source of cells that could be used to replace those damaged/diseased cells.

Human Type I Diabetes PB Plasma

ABC-TC4264 1 vial Ask for price
Description: Type I Diabetes peripheral blood plasma is obtained by centrifugation of the Type I Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type I PB plasma is available upon request.

Human Type II Diabetes PB Plasma

ABC-TC4266 1 vial Ask for price
Description: Type II Diabetes peripheral blood plasma is obtained by centrifugation of the Type II Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type II PB plasma is available upon request.

Preadipocytes, visc 1M cells, Diabetes Type I

LOPT-5023 each
EUR 1155.54

Preadipocytes, visc 1M cells, Diabetes Type II

LOPT-5024 each
EUR 1155.54

Type I Diabetes Serum, Human Donor

MBS170481-1Sample 1Sample
EUR 310

Type I Diabetes Serum, Human Donor

MBS170481-5Samples 5Samples
EUR 960

Type I Diabetes Serum, Human Donor

MBS170481-5x5Samples 5x5Samples
EUR 4110

Type II Diabetes Serum, Human Donor

MBS170482-1Sample 1Sample
EUR 310

Type II Diabetes Serum, Human Donor

MBS170482-5Samples 5Samples
EUR 960

Type II Diabetes Serum, Human Donor

MBS170482-5x5Samples 5x5Samples
EUR 4110

Preadipocytes, subcu 1M cells, Diabetes Type I

LOPT-5021 each
EUR 782.64

Preadipocytes, subcu 1M cells, Diabetes Type II

LOPT-5022 each
EUR 782.64

Plasma - Type II Diabetes - Human Patient

MBS170491-1Sample 1Sample
EUR 310

Plasma - Type II Diabetes - Human Patient

MBS170491-5Samples 5Samples
EUR 1005

Plasma - Type II Diabetes - Human Patient

MBS170491-5x5Samples 5x5Samples
EUR 4310

Plasma - Type I Diabetes - Patient Sample

MBS170490-1Sample 1Sample
EUR 310

Plasma - Type I Diabetes - Patient Sample

MBS170490-5Samples 5Samples
EUR 1005

Plasma - Type I Diabetes - Patient Sample

MBS170490-5x5Samples 5x5Samples
EUR 4310

Single Donor Human Type II Diabetes Semen

IRHUSMSDIBTII1ML each
EUR 842
Description: Single Donor Human Type II Diabetes Semen

Single Donor Human Type I Diabetes Urine

IRHUURESDIBTI250ML each
EUR 1063
Description: Single Donor Human Type I Diabetes Urine

Single Donor Human Type I Diabetes Urine

IRHUURESDIBTI50ML each
EUR 439
Description: Single Donor Human Type I Diabetes Urine

Single Donor Human Type II Diabetes Urine

IRHUURESDIBTII250ML each
EUR 1063
Description: Single Donor Human Type II Diabetes Urine

Single Donor Human Type II Diabetes Urine

IRHUURESDIBTII50ML each
EUR 439
Description: Single Donor Human Type II Diabetes Urine

Single Donor Human Type II Diabetes Semen

MBS8421302-1mL 1mL
EUR 1045

Single Donor Human Type II Diabetes Semen

MBS8421302-5x1mL 5x1mL
EUR 4460

Single Donor Human Type I Diabetes Urine

MBS8421330-250mL 250mL
EUR 1285

Single Donor Human Type I Diabetes Urine

MBS8421330-50mL 50mL
EUR 595

Single Donor Human Type I Diabetes Urine

MBS8421330-5x250mL 5x250mL
EUR 5540

Single Donor Human Type II Diabetes Urine

MBS8421331-250mL 250mL
EUR 1285

Single Donor Human Type II Diabetes Urine

MBS8421331-50mL 50mL
EUR 595

Single Donor Human Type II Diabetes Urine

MBS8421331-5x250mL 5x250mL
EUR 5540

Semen, Single Human Donor - Type II Diabetes

MBS173503-1Sample 1Sample
EUR 815

Semen, Single Human Donor - Type II Diabetes

MBS173503-5x1Sample 5x1Sample
EUR 3455

Whole Blood - Type I Diabetes - Patient Sample

MBS170486-1Sample 1Sample
EUR 310

Whole Blood - Type I Diabetes - Patient Sample

MBS170486-5x1Sample 5x1Sample
EUR 4310

Whole Blood - Type II Diabetes - Patient Sample

MBS170487-1Sample 1Sample
EUR 310

Whole Blood - Type II Diabetes - Patient Sample

MBS170487-5x1Sample 5x1Sample
EUR 4310

D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type I

LOCC-2919 each
EUR 1920.94

D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type II

LOCC-2920 each
EUR 1920.94

HighQC™ Human IPS Cell (Episomal/ Diabetes Type II/ Adipose)

ABC-SC0011T 1 vial Ask for price
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions.

D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type I

LOCC-2914 each
EUR 1888.07

D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type II

LOCC-2916 each Ask for price

HighQC™ Human IPS Cell (IPSC From PBMC/ Diabetes Type II/ Episomal)

ABC-SC0009T 1 vial Ask for price
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions.

D-HCAEC – Diseased Human Coronary Artery Endothelial – Diabetes Type II

LOCC-2922 each
EUR 1884.64

Human Type I Diabetes Peripheral Blood Mononuclear Cells

ABC-TC4263 1 vial Ask for price
Description: Peripheral blood mononuclear cells are isolated from Type I Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type I PBMCs is available upon request.

Human Type II Diabetes Peripheral Blood Mononuclear Cells

ABC-TC4265 1 vial Ask for price
Description: Human Peripheral Blood Mononuclear Cells are available as positive and negative controls for T-cell monitoring in ELISPOT, ELISA, cytokine bead array, tetramer/pentamer, and flow cytometry assays. A peripheral blood mononuclear cell is defined as any blood cell with a round nucleus. These blood cells are a critical component in the immune system to fight infection and adapt to intruders. The lymphocyte population consists of CD4+ and CD8+ T cells, B cells and Natural Killer cells, CD14+ Monocytes, and Basophils/Neutrophils/Eosinophils/Dendritic cells. These cells are often extracted from whole blood or from leukopacks using ficoll, a hydrophilic polysaccharide that separates layers of blood, with monocytes and lymphocytes forming a buffy coat under a layer of plasma.Samples from each donor are tested via PCR to confirm non-reactivity. Peripheral blood mononuclear cells are isolated from Type II Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type II PBMCs is available upon request.

D-Adipose-Derived stem cells, human, Type I Diabetes

LOPT-5007 each
EUR 748.19

D-Adipose-Derived stem cells, human, Type II Diabetes

LOPT-5008 each
EUR 748.19

D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type I

LOCC-2917 each
EUR 1880.03

D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type II

LOCC-2918 each
EUR 1880.03

D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type I

LOCC-2927 each
EUR 1299.42

D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type II

LOCC-2928 each Ask for price

HighQC™ Human IPS Cell (IPSC From Fibroblast/ Diabetes Type II/ Episomal)

ABC-SC0010T 1 vial Ask for price
Description: Gentaur is is proud to offer human iPS cell lines derived from the human dermal fibroblasts from patients with Type 2 Diabetes (T2D). The pertinent donor information is available upon request. These iPS cells are established from a single clone and expanded in feeder-free conditions. Normal human iPS cell lines are also available as separate products . We also provide custom iPSC generation and iPSC differentiation services to meet your needs.

D-HCAEC – Diseased Human Coronary Artery Endothelial Cells – Diabetes Type I

LOCC-2921 each
EUR 1884.64

D-HEK-Ad – Diseased Human Adult Epidermal Keratinocytes – Diabetes Type II

LOCC-2926 each
EUR 841.52

D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type I

LOCC-2923 each
EUR 1920.94

D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type II

LOCC-2924 each Ask for price

D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type II

LOCC-2913 each
EUR 1935.75

D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type I

LOCC-2915 each Ask for price

D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type I

LOCC-2929 each
EUR 1169.49

D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type II

LOCC-2930 each Ask for price

D-RPTEC – Diseased Human Renal Proximal Tubule Epithelial Cells – Diabetes Type II

LOCC-2925 each
EUR 2091.71

Linearity FD Special Diabetes

K889M-5 5 x 2 mL
EUR 374

HighQC™ Human Bone Marrow Derived Mesenchymal Stem Cell/ Type II Diabetes Patient

ABC-SC0027T 1 vial Ask for price
Description: Human MSCs (Bone Marrow Derived) from a single adult donor clinically diagnosed with Type II Diabetes. The MSCs are compatible with our MSC Expansion Medium for Bone Marrow Derived MSCs.All of the cells provided are tested and are negative for HIV-1, HIV-2, Hepatitis B and Hepatitis C as detected by PCR. The cells are confirmed to be negative for mycoplasma and other detectable microbial contamination.

Human Diabetes Lung Tissue Lysate

IHULGDIBTL100UG each
EUR 1413
Description: Human Diabetes Lung Tissue Lysate

Single Donor Human Diabetes Serum

ISERSDIB each
EUR 209
Description: Single Donor Human Diabetes Serum

Single Donor Human Diabetes Serum

MBS8421607-INQUIRE INQUIRE Ask for price

Human Diabetes Lung Tissue Lysate

MBS8414460-01mg 0.1mg
EUR 1810

Human Diabetes Lung Tissue Lysate

MBS8414460-5x01mg 5x0.1mg
EUR 7965

Human Diabetes Colon Tissue Lysate

IHUCLNDIBTL100UG each
EUR 1413
Description: Human Diabetes Colon Tissue Lysate

Human Diabetes Ileum Tissue Lysate

IHUILMDIBTL100UG each
EUR 1413
Description: Human Diabetes Ileum Tissue Lysate

Single Donor Human Diabetes Plasma

IPLASDIB each
EUR 209
Description: Single Donor Human Diabetes Plasma

Single Donor Human Diabetes Plasma

MBS8421060-INQUIRE INQUIRE Ask for price

Human Diabetes Ileum Tissue Lysate

MBS8413586-01mg 0.1mg
EUR 1810

Human Diabetes Ileum Tissue Lysate

MBS8413586-5x01mg 5x0.1mg
EUR 7965

Human Diabetes Colon Tissue Lysate

MBS139594-01mg 0.1mg
EUR 1810

Human Diabetes Colon Tissue Lysate

MBS139594-5x01mg 5x0.1mg
EUR 7965

Human Diabetes Jejunum Tissue Lysate

IHUJEJDIBTL100UG each
EUR 1413
Description: Human Diabetes Jejunum Tissue Lysate

Human Diabetes Stomach Tissue Lysate

IHUSTDIBTL100UG each
EUR 1413
Description: Human Diabetes Stomach Tissue Lysate

Human Diabetes Jejunum Tissue Lysate

MBS8413808-01mg 0.1mg
EUR 1810

Human Diabetes Jejunum Tissue Lysate

MBS8413808-5x01mg 5x0.1mg
EUR 7965

Human Diabetes Stomach Tissue Lysate

MBS8420033-01mg 0.1mg
EUR 1810

Human Diabetes Stomach Tissue Lysate

MBS8420033-5x01mg 5x0.1mg
EUR 7965

Human Diabetes Duodenum Tissue Lysate

IHUDUODIBTL100UG each
EUR 1413
Description: Human Diabetes Duodenum Tissue Lysate

Human Diabetes Pancreas Tissue Lysate

IHUPCSDIBTL100UG each
EUR 1413
Description: Human Diabetes Pancreas Tissue Lysate

Human Diabetes Pancreas Tissue Lysate

MBS8416917-01mg 0.1mg
EUR 1810

Human Diabetes Pancreas Tissue Lysate

MBS8416917-5x01mg 5x0.1mg
EUR 7965

 

, , , , , , , , , , , , , ,

Post navigation

Leave a Reply

Your email address will not be published. Required fields are marked *